MRA techniques without contrast address NSF fears
Noncontrast MR angiography sequences could one day replace conventional contrast-enhanced MRA for evaluation of major arteries and veins of the thoracic region. They may provide an alternative for patients who risk developing nephrogenic systemic fibrosis and other contrast-related complications.
Noncontrast MR angiography sequences could one day replace conventional contrast-enhanced MRA for evaluation of major arteries and veins of the thoracic region. They may provide an alternative for patients who risk developing nephrogenic systemic fibrosis and other contrast-related complications.
Dr. Anderanik Tomasian, a radiologist at the University of California, Los Angeles, and colleagues enrolled 30 consecutive patients with known or suspected disease who underwent free-breathing ECG-gated steady-state free precession noncontrast MRA and high-resolution 3D contrast-enhanced MRA of the thorax, both at 1.5T. They found that noncontrast MRA allowed diagnosis of aortic thrombosis, dilatation, coarctation, and dissection as well as diagnosis of superior and inferior vena cava conditions. Total scanning time with this sequence ranged from five to 10 minutes.
Tomasian presented the data at the 2007 North American Society for Cardiac Imaging meeting in Washington, DC.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
